http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation
-
Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch
-
Ryoncil® Revenues Increase 66% in Second Quarter Post Launch
-
Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access
-
Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs
-
Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences
-
Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes
-
Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®
-
Successful Commercial Launch of Ryoncil®
-
Mesoblast Limited (MSB) received seven years of orphan-drug exclusive approval from US FDA
-
FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®
-
Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025
-
First Three Children to Commence Treatment With Ryoncil®
-
Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States
-
Mesoblast Added to S&P/ASX 200 INDEX
-
Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter
-
Mesoblast Financial Results and Corporate Update Webcast
-
Dr. Gregory George MD PhD Joins Mesoblast Board
-
Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now
-
Ryoncil® FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings
-
Ryoncil® Commercial Launch Update and Product Pipeline
-
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024
-
Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy
-
FDA Grants Revascor® (Rexlemestrocel-L) Regenerative Medicine Advanced Therapy (RMAT) Designation in Children with Congenital Heart Disease
-
Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation
-
Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2024
-
Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch
-
Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2024
-
Mesoblast Financial Results and Corporate Update Webcast
-
Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2024
-
Mesoblast Limited (MESO): FDA Accepts BLA for Ryoncil in Children With Steroid-Refractory Acute Graft-Versus-Host Disease
-
FDA Accepts Mesoblast’s Biologics License Application (BLA) for Ryoncil® in Children With Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
-
Patient Enrollment Commenced in Pivotal Phase 3 Trial of Rexlemestrocel-L for Chronic Low Back Pain
-
Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children with Steroid-Refractory Acute Graft-Versus-Host Di
-
Mesoblast to File Biologics License Application for Ryoncil® FDA Approval Next Week
-
Mesoblast Corporate Presentation at Investor Conference
-
Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024
-
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Ste
-
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
-
Mesoblast (MSB) FDA Supports Accelerated Approval Pathway for Rexlemestrocel-L
-
United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)
-
Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023
-
United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
-
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023
-
United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
-
Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease
-
Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD
-
Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023
-
Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee
-
Key Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL Approval
